Residency · Residency · Radiation Oncology
PACIFIC Trial and the Thoracic RT-Immunotherapy Paradigm
Introduction
The PACIFIC trial stands as a landmark study in thoracic oncology, fundamentally changing the treatment landscape for unresectable Stage III non-small cell lung cancer (NSCLC). It established consolidative durvalumab, an anti-PD-L1 immune checkpoint inhibitor, following concurrent chemoradiation as the new standard of care. This lecture delves into the trial's design, outcomes, subgroup analyses, and its broader implications for integrating radiotherapy and immunotherapy in thoracic malignancies.
Background and Rationale
Stage III NSCLC Before PACIFIC
Prior to the PACIFIC trial, the standard treatment for unresectable Stage III NSCLC involved concurrent chemoradiation, typically delivering 60 to 66 Gy alongside a platinum-based doublet chemotherapy regimen. Despite this aggressive approach, median overall survival hovered around 28 months, with five-year survival rates ranging between 15 and 25%. For two decades before PACIFIC, there had been little progress in improving these outcomes. Attempts at maintenance chemotherapy or consolidative docetaxel after chemoradiation yielded minimal survival benefits, underscoring the need for novel therapeutic strategies.
Scientific Rationale
The rationale for combining immunotherapy with thoracic radiation stems from the immunogenic effects of concurrent chemoradiation. This treatment induces immunogenic cell death and upregulates PD-L1 expression on tumor cells, creating a tumor microenvironment more susceptible to immune attack. Radiation also stimulates the production of type I interferons, which enhance dendritic cell activation and antigen presentation. Importantly, residual micrometastatic disease persisting after chemoradiation represents a critical target for immune-mediated eradication. Thus, consolidative immune checkpoint inhibition can leverage this immunogenic milieu to improve disease control and survival.
Trial Design
Study Population
The PACIFIC trial enrolled patients with unresectable Stage III NSCLC, including stages IIIA, IIIB, and IIIC. Eligible participants had completed concurrent platinum-based chemoradiation delivering between 54 and 66 Gy without evidence of disease progression. Patients were required to have a World Health Organization performance status of 0 or 1 and were randomized within 1 to 42 days after completing radiotherapy. Exclusion criteria included prior immunotherapy, active autoimmune diseases, and pneumonitis necessitating more than 10 mg of prednisone daily.
Randomization
Participants were randomized in a 2:1 ratio to receive either durvalumab at 10 mg/kg intravenously every two weeks or placebo. Treatment continued for up to 12 months. Randomization was stratified by age, sex, and smoking status to ensure balanced distribution of these prognostic factors.
Co-Primary Endpoints
The trial's co-primary endpoints were progression-free survival (PFS) and overall survival (OS), designed to assess both disease control and long-term benefit.
Results
Progression-Free Survival
Durvalumab significantly prolonged median progression-free survival to 16.9 months compared to 5.6 months with placebo, corresponding to a hazard ratio (HR) of 0.52 (95% confidence interval [CI] 0.42-0.65; p < 0.001). This PFS advantage was consistent across all prespecified subgroups. At three years, the PFS rate was 33.3% in the durvalumab arm versus 19.0% in the placebo group.
Overall Survival
The median overall survival was markedly improved with durvalumab, reaching 47.5 months compared to 29.1 months for placebo. The hazard ratio for death was 0.72 (95% CI 0.59-0.89; p = 0.0025). Five-year overall survival rates were 42.9% with durvalumab versus 33.4% with placebo, representing an unprecedented survival improvement in Stage III NSCLC.
Updated Long-Term Data (5-Year)
Five-year follow-up data confirmed durable benefits, with PFS rates of 33.1% versus 19.0% and OS rates of 42.9% versus 33.4% favoring durvalumab. The survival curve exhibited a durable tail, suggesting potential cure in a subset of patients. These benefits were maintained across most patient subgroups.
Key Subgroup Analyses
Timing of Durvalumab Initiation
Patients who initiated durvalumab within 14 days of completing chemoradiation experienced the best outcomes, with an overall survival hazard ratio of 0.42 compared to 0.81 for those starting between 14 and 42 days. Although the interaction was not statistically significant, this finding supports the clinical practice of starting durvalumab as early as possible after chemoradiation.
PD-L1 Expression
Patients with PD-L1 expression greater than 1% derived clear benefit from durvalumab, with an OS hazard ratio of 0.59. In contrast, those with PD-L1 less than 1% showed a less certain benefit, with an OS hazard ratio of 0.89 and confidence intervals crossing unity. Regulatory approvals vary: the FDA approved durvalumab regardless of PD-L1 status, whereas the EMA restricts use to patients with PD-L1 above 1%. It is important to note that PD-L1 status was unknown in approximately 36% of trial participants, limiting the strength of these subgroup analyses.
EGFR and ALK Status
Patients harboring EGFR mutations or ALK rearrangements did not appear to benefit from durvalumab, although small sample sizes preclude definitive conclusions. These patients may derive greater benefit from targeted therapies rather than immunotherapy in this setting.
Safety Profile
Adverse Events
The incidence of any-grade adverse events was high but comparable between arms: 96.8% in the durvalumab group versus 94.9% in placebo. Grade 3 to 4 adverse events occurred in 30.5% of patients receiving durvalumab compared to 26.1% with placebo. Treatment discontinuation due to adverse events was more frequent with durvalumab (15.4% versus 9.8%).
Pneumonitis (Key Toxicity)
Pneumonitis, including radiation pneumonitis, was the most significant toxicity. Any-grade pneumonitis occurred in 33.9% of durvalumab-treated patients versus 24.8% in the placebo group. Grade 3 to 4 pneumonitis was relatively uncommon, occurring in 3.4% versus 2.6%. Most cases were low-grade and manageable with corticosteroids. Pneumonitis led to treatment discontinuation in 6.3% of patients on durvalumab compared to 4.3% on placebo. Overall, no unexpected safety signals emerged, and the toxicity profile was considered manageable.
Immune-Related Adverse Events
Immune-related adverse events included thyroid disorders in approximately 11% of patients, with hypothyroidism being the most common. Hepatitis, colitis, and dermatitis were less frequent, each occurring in fewer than 3% of patients. These events were managed according to established immune-related adverse event guidelines.
Clinical Implementation
Patient Selection
Durvalumab consolidation is indicated for all patients with unresectable Stage III NSCLC who complete concurrent chemoradiation without disease progression and maintain a performance status of 0 or 1 at the time of initiation. Patients with active autoimmune diseases or those requiring high-dose steroids are generally excluded. While PD-L1 testing is recommended, it is not mandatory for treatment initiation in most regions.
Practical Considerations
Durvalumab should be started as soon as possible after chemoradiation, ideally within 14 days. Before initiation, patients should have recovered sufficiently to ensure no grade 2 or higher pneumonitis is present. Treatment duration is up to 12 months or until disease progression or intolerance. Surveillance imaging is typically performed every two to three months during therapy.
Radiation Planning Considerations
Radiation planning should employ intensity-modulated radiation therapy (IMRT) or volumetric modulated arc therapy (VMAT) techniques to minimize lung dose parameters such as V20 and mean lung dose, as lower lung doses may reduce the risk of pneumonitis when durvalumab is administered subsequently. Cardiac dose minimization is also important, given emerging data on cardiac toxicity with combined radiotherapy and immune checkpoint inhibitors. Elective nodal irradiation remains standard practice according to Radiation Therapy Oncology Group (RTOG) guidelines.
Beyond PACIFIC: Expanding the Paradigm
PACIFIC-2 (Concurrent Durvalumab + ChemoRT)
The PACIFIC-2 trial is investigating the safety and efficacy of administering durvalumab concurrently with chemoradiation rather than sequentially. This randomized phase III study may further shift the treatment paradigm by introducing immunotherapy earlier in the course of treatment. Results are awaited.
PACIFIC-5 and PACIFIC-9
PACIFIC-5 is evaluating the use of durvalumab following sequential chemoradiation compared to concurrent chemoradiation, while PACIFIC-9 explores durvalumab in combination with novel immune checkpoint inhibitor agents. These studies aim to refine and expand the immunotherapy-radiotherapy approach.
Other Agents
Additional trials are exploring other immune checkpoint inhibitors in combination with chemoradiation. KEYNOTE-799 is a single-arm study of pembrolizumab plus chemoradiation showing promising results. CheckMate 73L combines nivolumab and ipilimumab with chemoradiation. Multiple ongoing trials are assessing various immune checkpoint inhibitor combinations to optimize outcomes.
Induction Immunotherapy Before ChemoRT
An emerging strategy involves administering immune checkpoint inhibitors prior to chemoradiation to reduce tumor burden and enhance immune priming. Trials such as SPRINT and AFT-16 are evaluating this approach, which has the potential to further improve outcomes beyond the current PACIFIC paradigm.
Key Clinical Pearls
The PACIFIC trial demonstrated that consolidative durvalumab after chemoradiation improves five-year overall survival from 33% to 43% in Stage III NSCLC, marking a significant advance in treatment. Initiating durvalumab within 14 days of completing chemoradiation yields the best outcomes. Pneumonitis remains the key toxicity, with grade 3 to 4 rates around 3.4%, necessitating careful clinical monitoring. Patients with PD-L1 expression below 1% may derive less benefit, although this subgroup analysis is limited and should inform shared decision-making. The PACIFIC paradigm has spurred numerous trials exploring concurrent and neoadjuvant immunotherapy combinations with thoracic radiation, signaling a new era in lung cancer treatment.
References
- Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(20):1919-1929.
- Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379(24):2342-2350.
- Faivre-Finn C, Vicente D, Kurata T, et al. Four-year survival with durvalumab after chemoradiotherapy in stage III NSCLC -- an update from the PACIFIC trial. J Thorac Oncol. 2021;16(5):860-867.
- Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):1301-1311.